BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

Nkarta had already beaten expectations by pricing its upsized IPO at $18, but its triple-digit aftermarket gains provided further evidence that the powerful appetite for new biotech listings extends to preclinical companies. The company more...
BioCentury | Sep 4, 2019
Finance

Nkarta’s $114M series B to fund clinical NK cell programs, manufacturing facility

After stretching its $11.5 million series A round to bring its most advanced preclinical NK cell programs within a year of IND submissions while assembling a management team with expertise ranging from discovery to manufacturing,...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | May 16, 2017
Distillery Techniques

Biomarkers

...1 with ZNF domain ( PRDM1 ; BLIMP1), B cell CLL lymphoma 10 (BCL10) , NK3 homeobox 1 (NKX3-1)...
...VIB), Leuven, Belgium email: jeanchristophe.marine@kuleuven.vib.be Hongjiang Li Aix-Marseille University Flanders Institute for Biotechnology (VIB) B cell CLL lymphoma 10 (BCL10) NK3 homeobox 1 (NKX3-1) PR...
BioCentury | May 16, 2013
Tools & Techniques

Myelination gets direct

Separate groups at the Case Western Reserve University School of Medicine and the Stanford University School of Medicine have developed similar approaches to directly reprogram rodent fibroblasts into oligodendrocyte progenitor cells. 1,2 The direct lineage...
BioCentury | May 2, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Fibroblast-derived induced oligodendrocyte progenitor cells (iOPCs) to treat myelination disorders Two separate studies developed methods to reprogram mouse fibroblasts into iOPCs...
BioCentury | Oct 18, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Thyroid disease NK2 homeobox 1 (NKX2-1; TTF1); paired box gene 8 (PAX8) Studies in cell culture and in mice suggest embryonic stem cell (ESC)-derived...
BioCentury | Sep 24, 2009
Distillery Therapeutics

Indication: Cancer

...Summary Licensing status Publication and contact information Cancer Prostate cancer Integrin a6 (ITGA6; VLA-6; CD49f); NK3 homeobox 1 (NKX3-1)...
...11 and 22 significantly correlated with prostate cancer. Two loci were within the ITGA6 and NKX3-1...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Transplantation

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Transplantation Tissue replacement GATA binding protein 4 (GATA4); T-box 5 (TBX5); NK2 transcription factor related, locus 5 (NKX2-5); SWI/SNF related, matrix...
BioCentury | Mar 19, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) NK2 homeobox 1 (NKX2-1; TTF1); NKX2-8 In vitro studies suggest that gene expression profiles of...
Items per page:
1 - 10 of 14